Anti-CD134 / OX40L Receptor Anticorps [Ber-ACT35] (FITC) (A279810)

Anti-CD134 / OX40L Receptor Antibody [Ber-ACT35] (FITC)

Mouse monoclonal [Ber-ACT35] antibody to CD134 / OX40L Receptor (FITC).

This antibody recognises CD134 also known as OX40 and TNFRSF4, a 50 kDa glycoprotein. CD134 is a type I transmembrane protein and a member of the tumor necrosis factor superfamily. CD134 is primarily expressed by activated T cells, although the level of expression differs according to T-cell subpopulations. OX40L also known as CD252 and TNFSF4 is the ligand of CD134. Upon ligand binding, the receptor recruits TNF receptor associated factor (TRAF) proteins which triggers downstream signaling events including NF?B pathways. This activation can regulate the number of effector T cells that accumulate in primary and secondary responses and determine the frequency of T cells that are generated (Croft 2010). Mutations affecting CD134 signaling has been linked with Kaposi sarcoma as well as susceptibility to infections. This clone Ber-ACT35 has been used in flow cytometry experiments to measure D134 expression levels on tumor-infiltrating Treg cells in mouse and human samples.

Flow Cytometry

Flow Cytometry: Neat, Use 4ul of the undiluted reagent to label 1x10⁶ cells in 100µl

Human, Primate

HTLV 1-transformed HUT-102 cells.

Mouse

Monoclonal

Ber-ACT35

IgG1

Protein A affinity chromatography of tissue culture supernatant.

Lot Specific

>95% (by SDS-PAGE).

Liquid

Supplied in Phosphate Buffered Saline with 0.2% BSA and <0.1% Sodium Azide.

Store undiluted at 4°C. Do not freeze! This product is photosensitive and should be protected from light.

Mouse anti Human CD134, clone Ber-ACT35 recognizes CD134 also known as OX40 and TNFRSF4, a 50 kDa glycoprotein. CD134 is a type I transmembrane protein and a member of the tumor necrosis factor superfamily. CD134 is primarily expressed by activated T cells, although the level of expression differs according to T-cell subpopulations (Buchan et al. 2018). OX40L also known as CD252 and TNFSF4 is the ligand of CD134. Upon ligand binding, the receptor recruits TNF receptor associated factor (TRAF) proteins which triggers downstream signaling events including NF?B pathways. This activation can regulate the number of effector T cells that accumulate in primary and secondary responses and determine the frequency of T cells that are generated (Croft 2010). Mutations affecting CD134 signaling has been linked with Kaposi sarcoma as well as susceptibility to infections. This clone Ber-ACT35 has been used in flow cytometry experiments to measure D134 expression levels on tumor-infiltrating Treg cells in mouse and human samples (Vargas et al. 2018).

ACT 35, ACT35, ACT35 antigen, ATC35 antigen, CD 134, CD134, CD134 antigen, IMD16, Lymphoid activation antigene ACT35, OX 40, OX40, OX40 antigen, OX40 cell surface antigen, OX40 homologue, OX40L receptor, TAX transcriptionally activated glycoprotein 1 receptor, TAX transcriptionally-activated glycoprotein 1 receptor, TNF receptor superfamily member 4, TNFRSF 4, TNFRSF4, TNR4_HUMAN, Tumor necrosis factor receptor superfamily member 4, Txgp 1l, Txgp1, Txgp1l

Ce produit est uniquement destiné à la recherche. Il n'est pas destiné à un usage diagnostique ou thérapeutique.